Pitolisant to Treat Excessive Daytime Sleepiness and Cataplexy in Adults with Narcolepsy: Rationale and Clinical Utility

被引:6
作者
Guevarra, Jay T. [1 ]
Hiensch, Robert [1 ]
Varga, Andrew W. [1 ]
Rapoport, David M. [1 ]
机构
[1] Icahn Sch Med Mt Sinai, Div Pulm Crit Care & Sleep Med, Mt Sinai Integrat Sleep Ctr, One Gustave L Levy Pl, New York, NY 10029 USA
关键词
narcolepsy; pitolisant; histamine; 3; receptor; excessive daytime sleepiness; cataplexy; HISTAMINE H-3 RECEPTOR; OREXIN-NULL MICE; CSF HISTAMINE; DOUBLE-BLIND; H3; RECEPTOR; WAKEFULNESS; HYPOCRETIN; MODAFINIL; NEURONS; EPIDEMIOLOGY;
D O I
10.2147/NSS.S264140
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Narcolepsy is a sleep disorder marked by chronic, debilitating excessive daytime sleepiness and can be associated with cataplexy, sleep paralysis and sleep-related hallucinations. Pharmacological therapy for narcolepsy primarily aims to increase wakefulness and reduce cataplexy attacks. Pitolisant is a first-in-class agent utilizing histamine to improve wakefulness by acting as an antagonist/inverse agonist of the presynaptic histamine 3 receptor. This review summarizes the clinical efficacy, safety and tolerability of pitolisant in treating the symptoms of narcolepsy. Randomized and observational studies demonstrate pitolisant to be effective in treating both hypersomnolence and cataplexy while generally being well tolerated at prescribed doses. The most common adverse reactions include headache, insomnia and nausea.
引用
收藏
页码:709 / 719
页数:11
相关论文
共 57 条
[1]  
[Anonymous], 2020, PLYM M PA
[2]  
[Anonymous], 2019, SLEEP
[3]   Management of Narcolepsy [J].
Barateau, Lucie ;
Lopez, Regis ;
Dauvilliers, Yves .
CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2016, 18 (10)
[4]   Cerebrospinal fluid histamine levels are decreased in patients with narcolepsy and excessive daytime sleepiness of other origin [J].
Bassetti, Claudio L. ;
Baumann, Christian R. ;
Dauvilliers, Yves ;
Croyal, Michael ;
Robert, Philippe ;
Schwartz, Jean-Charles .
JOURNAL OF SLEEP RESEARCH, 2010, 19 (04) :620-623
[5]  
Bauer Eric D, 2019, SLEEP S1, V42, pA243, DOI [10.1093/sleep/zsz067.609, DOI 10.1093/SLEEP/ZSZ067.609]
[6]   The cost utility of pitolisant as narcolepsy treatment [J].
Bolin, Kristian ;
Niska, Per-Ake ;
Pirhonen, Laura ;
Wasling, Pontus ;
Landtblom, Anne-Marie .
ACTA NEUROLOGICA SCANDINAVICA, 2020, 141 (04) :301-310
[7]  
Darien I., 2014, International classification of sleep disorders, V3rd
[8]  
DAUVILLIERS Y, 2019, SLEEP, V42
[9]   Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial [J].
Dauvilliers, Yves ;
Bassetti, Claudio ;
Lammers, Gert Jan ;
Amulf, Isabelle ;
Mayer, Geert ;
Rodenbeck, Andrea ;
Lehert, Philippe ;
Ding, Claire-Li ;
Lecomte, Jeanne-Marie ;
Schwartz, Jean-Charles .
LANCET NEUROLOGY, 2013, 12 (11) :1068-1075
[10]   Important decisions in choosing the pharmacotherapy for narcoleptics [J].
de Biase, Stefano ;
Gigli, Gian Luigi ;
Valente, Mariarosaria .
EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (05) :483-486